• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Skinovation Pharm

Skinovation Pharm

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. The Estée Lauder Companies Delivers Strong Sales and Earnings Growth in Fiscal 2016 Second Quarter

    The Estée Lauder Companies Delivers Strong Sales and Earnings Growth in Fiscal 2016 Second Quarter

  2. PharmaPoint Report: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023 - Market is currently dominated by Velcade and Revlimid - Research and Markets

    PharmaPoint Report: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023 - Market is currently dominated by Velcade and Revlimid - Research and Markets

  3. The Estée Lauder Companies Inc. Declares Quarterly Dividend of $.30 Per Share

    The Estée Lauder Companies Inc. Declares Quarterly Dividend of $.30 Per Share

  4. Estee Lauder beats expectations, but gives downbeat profit outlook

    Estee Lauder beats expectations, but gives downbeat profit outlook

  5. Global Optical Imaging Market - Projected to Reach $1.75 Billion by 2020 - Research and Markets

    Global Optical Imaging Market - Projected to Reach $1.75 Billion by 2020 - Research and Markets

  6. UPDATE: Worried about the Zika virus? Some airlines, cruise lines offering refunds and credits

    UPDATE: Worried about the Zika virus? Some airlines, cruise lines offering refunds and credits

  7. Coty Inc. Announces $500 Million Class A Share Repurchase Authorization

    Coty Inc. Announces $500 Million Class A Share Repurchase Authorization

  8. Osiris Therapeutics Announces Leadership Transition

    Osiris Therapeutics Announces Leadership Transition

  9. UPDATE: Why an early Alibaba backer is still betting on China

    UPDATE: Why an early Alibaba backer is still betting on China

  10. One big U.S. venture capital firm is still betting on China

    One big U.S. venture capital firm is still betting on China

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.